Oct 14, 2021

Featuring perspectives from Drs Edward Garon, Jarushka Naidoo, Harvey Pass and Heather Wakelee, including the following topics:

• Immunotherapy in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
  • Introduction: Tumor board discussions since ASCO 2021 (0:00)
  • Case: A woman in her early 60s with Stage IIA lung adenocarcinoma — PD-L1-negative, pan-wild type (8:00)
  • Case: A man in his mid-50s with Stage IIA squamous NSCLC — PD-L1 15% (22:44)
  • Case: A man in his early 90s with Stage IB lung adenocarcinoma — PD-L1 10% (31:47)
  • Key relevant data sets (39:07)
• Adjuvant Treatment of NSCLC with a Driver Mutation
  • Case: A man in his late 60s with Stage III lung adenocarcinoma — PD-L1 <1%, EGFR L858R mutation (43:31)
  • Case: A woman in her late 40s with Stage IIIA lung adenocarcinoma — PD-L1 50%, ALK mutation (53:53)

CME information and select publications